Here's Why Shares in PTC Therapeutics Soared This Week

Shares in PTC Therapeutics (NASDAQ: PTCT) surged by 17.5% in the week to Friday morning, as the market digested management's upbeat presentation at the Cantor Global Healthcare Conference on Wednesday.CEO Matthew Klein's presentation focused on the commercial market opportunity for Sephience, an orally administered therapy for treating phenylketonuria (PKU). Sephience has been approved in the U.S. and Europe, as it lowers the abnormally high levels of amino acid phenylalanine that builds up in PKU sufferers. It's a condition that puts severe dietary restrictions on PKU sufferers. Klein believes that the majority of patients on the drug will be responders and could achieve significant reductions in phenylalanine. PTC has a $1 billion commercial opportunity in the U.S. and a $500 million commercial opportunity outside the U.S. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool